Fosrenol Articles
Shire files Fosrenol law suit against Natco Pharma
6 April 2009
Shire files law suit to block Mylan's generic Fosrenol
30 March 2009
Mylan group sued over for first-to-file ANDAs
27 March 2009
Shire sues Barr over Fosrenol patents
23 March 2009
Shire launches Fosrenol in Japan
16 March 2009
Shire told Mylan and Barr seeking generic Fosrenol appro
16 February 2009
3rd-qtr new product sales deliver for Shire, but the firm posts earnings drop on charges
10 November 2008
Shire move to improve CKD management adherence
7 April 2008
Shire posts "best ever" results
12 November 2007
Shire's Fosrenol fares well in Ph II CKD study
12 November 2007
FDA's CRDAC votes to expand P binders in CKD
29 October 2007
Shire's 1st-qtr income soars 85% on sales
7 May 2007
Shire launches Fosrenol in UK
5 March 2007
Bayer Yakuhin files Fosrenol in Japan
22 December 2006
Fosrenol as effective as standard therapy in hyperphosphatemia
27 November 2006
AnorMed set to receive $3M from Shire
2 October 2006
Fosrenol approved in Germany for hyperphosphatemia
25 September 2006
Shire earnings down on TKT acquisition
7 August 2006
Shire's net income improves 75% in 1st qtr
8 May 2006
Shire finds in vitro efficacy for Fosrenol
23 May 2005
Bayer Healthcare looks set to expand in Japan
18 April 2005
Upbeat forecast from Shire Pharma
11 April 2005
Shire announces 13% growth in revenue
7 March 2005
Stock Commentary - Europe
8 November 2004
US FDA approves Shire's Fosrenol
1 November 2004
Shire's Fosrenol faces delay for US approval
26 July 2004
UPDATE: Shire's Fosrenol faces delay for US approval
26 July 2004
Shire pays $31M for Fosrenol patent rights
29 March 2004
Shire's Fosrenol gets first approval, in Sweden
29 March 2004
Strong performace for Shire in 2003
22 March 2004
Bayer licenses Shire's Fosrenol in Japan
15 December 2003
Positive new findings for Shire's Fosrenol
24 November 2003
Shire beats expectations in third quarter as ADHD product sales soar
17 November 2003
Stock Commentary - Europe
21 July 2003
Shire's Fosrenol cuts phosphate in a week
7 July 2003
Fosrenol shows long term benefit in ESRD
23 June 2003
Shire's Fosrenol is approvable, says FDA
10 March 2003
Stock Commentary - Europe
10 March 2003
Shire's profits up on switching strategy
3 March 2003
Altair unveils Renagel, Fosrenol rival
22 July 2002
Genzyme General revises 2002 financial guidance
24 June 2002
Shire's Fosrenol clears bone safety hurdle
17 June 2002
Shires files Foznol/Fosrenol in USA
6 May 2002
Revenues in 1st-qtr rise 30% at Shire
6 May 2002
Showing 1-52 of 52 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
